featured
Tucatinib Added to Trastuzumab and Capecitabine for Pretreated HER2+ Metastatic Breast Cancer ± Brain Metastases
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Annals of Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Tucatinib vs Placebo Added to Trastuzumab and Capecitabine for Patients with Pretreated HER2+ Metastatic Breast Cancer with and without Brain Metastases (HER2CLIMB): Final Overall Survival Analysis
Ann. Oncol 2021 Dec 22;[EPub Ahead of Print], G Curigliano, V Mueller, V Borges, E Hamilton, S Hurvitz, S Loi, R Murthy, A Okines, E Paplomata, D Cameron, LA Carey, K Gelmon, GN Hortobagyi, I Krop, S Loibl, M Pegram, D Slamon, J Ramos, W Feng, E WinerFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.